Garry E Menzel Insider Trading
Get free email notifications about insider trading for Garry E Menzel.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insider Transactions | Monthly Overview
Get the latest insider transactions of Garry E Menzel. Garry E Menzel is an COO & Executive VP, Finance in Regulus Therapeutics Inc. ($RGLS) and a Director in Stoke Therapeutics, Inc. ($STOK) and a Director in Black Diamond Therapeutics, Inc. ($BDTX) and a President & CEO in TCR2 THERAPEUTICS INC. ($TCRR) and a President and CEO in TCR2 THERAPEUTICS INC. ($TCRR).
Address: C/O REGULUS THERAPEUTICS INC. 3545 JOHN HOPKINS COURT, SUITE 210 SAN DIEGO 92121 CA
Companies in which Garry E Menzel is an Insider
Black Diamond Therapeutics, Inc.
Trading Symbol: BDTXIndustry: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
Position of Garry E Menzel: Director
Holdings: 51,825 shares
Latest Transaction: Jun 22 2021
Last 4 weeks trend: HOLD
Last 3 months trend: HOLD View transactions
Regulus Therapeutics Inc.
Trading Symbol: RGLSIndustry: PHARMACEUTICAL PREPARATIONS [2834]
Position of Garry E Menzel: COO & Executive VP, Finance
Holdings: 0 shares
Current Value: $0
Latest Transaction: Dec 13 2012
$RGLS Market Capitalization: $72.77M
$RGLS Previous Close: $1.40
Last 4 weeks trend: HOLD
Last 3 months trend: HOLD View transactions
Stoke Therapeutics, Inc.
Trading Symbol: STOKIndustry: PHARMACEUTICAL PREPARATIONS [2834]
Position of Garry E Menzel: Director
Holdings: 0 shares
Latest Transaction: Jan 27 2021
Last 4 weeks trend: HOLD
Last 3 months trend: HOLD View transactions
TCR2 THERAPEUTICS INC.
Trading Symbol: TCRRIndustry: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
Position of Garry E Menzel: President and CEO, President & CEO
Holdings: 3,399 shares
Latest Transaction: Mar 08 2021
Last 4 weeks trend: HOLD
Last 3 months trend: HOLD View transactions
Latest Insider Trading Transactions of Garry E Menzel
Sentiment: All, BDTX, RGLS, STOK, TCRR
Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
---|---|---|---|---|---|---|---|---|---|---|---|
Jun 22 2021 | BDTX | Black Diamond Ther ... | Menzel Garry E | Director | Option Exercise | A | 12.55 | 15,000 | 188,250 | 15,000 | |
Apr 23 2021 | BDTX | Black Diamond Ther ... | Menzel Garry E | Director | Option Exercise | A | 24.33 | 14,921 | 363,028 | 14,921 | |
Apr 23 2021 | BDTX | Black Diamond Ther ... | Menzel Garry E | Director | Option Exercise | A | 24.33 | 14,921 | 363,028 | 14,921 | |
Mar 08 2021 | TCRR | TCR2 THERAPEUTICS ... | Menzel Garry E | President and CEO | Grant | A | 16.12 | 686 | 11,061 | 4,085 | 3.4 K to 4.1 K (+20.18 %) |
Mar 08 2021 | TCRR | TCR2 THERAPEUTICS ... | Menzel Garry E | President and CEO | Grant | A | 10.10 | 1,132 | 11,431 | 3,399 | 2.3 K to 3.4 K (+49.93 %) |
Jan 27 2021 | STOK | Stoke Therapeutics ... | Menzel Garry E | Director | Option Exercise | A | 28.57 | 29,555 | 844,386 | 29,555 | |
Dec 11 2020 | TCRR | TCR2 THERAPEUTICS ... | Menzel Garry E | President and CEO | Option Exercise | A | 31.38 | 245,000 | 7,688,100 | 245,000 |